ROSUMEGA®

ROSUMEGA®
Product Description

(1) Mixed Hyperlipidemia

(2) Once daily, 2~4 soft capsules per day

(3) Dual Effect to reduce LCL-C and TG Level by patented technology* (3-layer coating)

(4) Combo’s additional decrease effect in residual cardiovascular risk & Omega-3’s multiple effects 
(Lowering blood pressure, reducing fatty liver, antiarrhythmic effect)

Kuhnil Pharm

  • KR
  • 2023
    On CPHI since
  • 250 - 499
    Employees
Company types
Academic/Research
CMO/CDMO
Distributor/Import Export
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
Specifications
  • Details
    Rosuvastatin calcium 5mg + Omega-3 acid ethylesters 90 1000mg
    (EPA ethylester 460mg + DHA ethylester 380mg)

  • Selling Points
    Cardiovascular Health; Product Features; Rosumega, which was launched in Korea in 2017, is a fixed dose combination of omega-3 and rosuvastatin.
    Multilayer coating technology was developed and applied for this specific product.

    Rosumega is the first fixed dose combination drug approved in Europe developed by a Korean company. It obtained approval in EU in 2020 (specifically in Netherlands and Italy) based on the phase 3 clinical trial carried out in Korea.
    We expect the sales of Rosumega to reach over 10 million this year and continued growth.

Kuhnil Pharm

  • KR
  • 2023
    On CPHI since
  • 250 - 499
    Employees
Company types
Academic/Research
CMO/CDMO
Distributor/Import Export
Generics/Biosimilars Manufacturer
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)

More Products from Kuhnil Pharm (4)

  • OMACOR® MINI CAPSULES

    Product OMACOR® MINI CAPSULES

    (1) Hypertriglyceridemia; Hyperlipidemia

    (2) Once daily, 2g or up to 4g if necessary

    (3) Ideal package for administration of ESC recommended strength of Omega-3          (ESC: European Society of Cardiology)

    (4) Easy to swallow, patient-friendly dosage form
  • EXFFERIDE® POWDER

    Product EXFFERIDE® POWDER

    (1) Chronic iron overload due to blood transfusions
    (2) Once daily; in fasting state

    (3) Easier administration of powder formulation compared to the original’s dispersible tablet 


    (4) Wider range of dosage strength
     
    (5) KR-1695970 (Expiration date: ...
  • DESMOPRESSIN OD!FS

    Product DESMOPRESSIN OD!FS

    (1) Nocturnal enuresis

    (2) Once daily; 0.1 or up to 0.4mg before bedtime 


    (3) No water needed and relieves stress taking medicine before bedtime

    (4) No residual feeling after administration & Sweet taste 


  • TADALAFIL OD!FS

    Product TADALAFIL OD!FS

    (1) Erectile dysfunction
    (2) Once Daily; before sexual activity

    (3) Improved privacy with extra-thin sachet

Kuhnil Pharm resources (1)